BARCELONA, Spain,
28
August
2017
|
00:00
Europe/Amsterdam

ESC Congress 2017: BIOTRONIK’s Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

Landmark Data Published by The Lancet Demonstrates Statistically Significant Lower Event Rates with Orsiro

BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the European Society of Cardiology’s ESC Congress 2017 and published by The Lancet show 6.2 percent versus 9.6 percent 12-month TLF rate, demonstrating statistically significant improved clinical outcomes with Orsiro in percutaneous coronary intervention (PCI).

This pivotal US investigational device exemption (IDE) trial included a large, complex patient population and was designed in collaboration with the FDA to support an upcoming premarket approval submission. Orsiro is currently commercially available in more than 100 countries worldwide.

 

References:

1 CAUTION – Investigational device in the United States. Limited by US law to investigational use.

2 Xience is a registered trademark of Abbott Cardiovascular Systems.

3 Not currently available in the United States.

About BIOTRONIK:

At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.